Stephen Moran, Ph.D., was appointed Global Program Head, Neuroendocrine Tumors & Other Radiosensitive Cancers for Advanced Accelerator Applications (AAA), a Novartis company in October 2020. He is also a member of the Oncology Development Unit Leadership Team at Novartis. Prior to joining AAA, Stephen was Global Head of Novartis Strategy, since 2016. As Strategy Global Head, Stephen played a key role in defining the company’s strategy, prioritizing critical actions needed to deliver on the mission to discover new ways to extend and improve peoples’ lives. He also led numerous strategic initiatives, including gene therapy (AveXis, now Novartis Gene Therapies), RNA (The Medicines Company), precision medicine and digital strategies. Stephen joined Novartis in 2015 as Strategic Assistant to the CEO, a position he held for two years. Prior to this, he was an associate principal at McKinsey & Company serving as a leader in the healthcare practice. At McKinsey, Stephen focused on health system sustainability, research and development strategy, and the economic analysis of clinical interventions across disease pathways. Stephen holds a Bachelor of Arts and a Master of Science in Biochemistry from the University of Cambridge in the United Kingdom, including an undergraduate exchange program at the Massachusetts Institute of Technology. He also received a Doctorate from the University of Oxford in Biophysics where he lectured on thermodynamics, quantum mechanics and electromagnetism as applied to biology. Stephen has also been a guest lecturer in strategy at the University of St. Gallen International Executives MBA, masters and bachelor courses, and received the Young Investigator of the Year award in 2006 from Biochemical Journal.